{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:11:30Z","timestamp":1794957090568,"version":"4.9.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"45","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Restrictive cardiomyopathy (RCM) is a heterogeneous group of diseases characterized by restrictive left ventricular pathophysiology, i.e. a rapid rise in ventricular pressure with only small increases in filling volume due to increased myocardial stiffness. More precisely, the defining feature of RCM is the coexistence of persistent restrictive pathophysiology, diastolic dysfunction, non-dilated ventricles, and atrial dilatation, regardless of ventricular wall thickness and systolic function. Beyond this shared haemodynamic hallmark, the phenotypic spectrum of RCM is wide. The disorders manifesting as RCM may be classified according to four main disease mechanisms: (i) interstitial fibrosis and intrinsic myocardial dysfunction, (ii) infiltration of extracellular spaces, (iii) accumulation of storage material within cardiomyocytes, or (iv) endomyocardial fibrosis. Many disorders do not show restrictive pathophysiology throughout their natural history, but only at an initial stage (with an evolution towards a hypokinetic and dilated phenotype) or at a terminal stage (often progressing from a hypertrophic phenotype). Furthermore, elements of both hypertrophic and restrictive phenotypes may coexist in some patients, making the classification challenge. Restrictive pathophysiology can be demonstrated by cardiac catheterization or Doppler echocardiography. The specific conditions may usually be diagnosed based on clinical data, 12-lead electrocardiogram, echocardiography, nuclear medicine, or cardiovascular magnetic resonance, but further investigations may be needed, up to endomyocardial biopsy and genetic evaluation. The spectrum of therapies is also wide and heterogeneous, but disease-modifying treatments are available only for cardiac amyloidosis and, partially, for iron overload cardiomyopathy.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac543","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T17:05:15Z","timestamp":1663347915000},"page":"4679-4693","source":"Crossref","is-referenced-by-count":176,"title":["Restrictive cardiomyopathy: definition and diagnosis"],"prefix":"10.1093","volume":"43","author":[{"given":"Claudio","family":"Rapezzi","sequence":"first","affiliation":[{"name":"Cardiologic Centre, University of Ferrara , Via Savonarola, 9, 44121 Ferrara , Italy"},{"name":"Maria Cecilia Hospital, GVM Care & Research , Via Corriera, 1, 48033 Cotignola, Ravenna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, piazza Martiri della Libert\u00e0 33 , 56127 Pisa , Italy"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio, via Moruzzi 1 , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-340X","authenticated-orcid":false,"given":"Andrea","family":"Barison","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, piazza Martiri della Libert\u00e0 33 , 56127 Pisa , Italy"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio, via Moruzzi 1 , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, piazza Martiri della Libert\u00e0 33 , 56127 Pisa , Italy"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio, via Moruzzi 1 , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Giacomo Puccini, 50 , 34148 Trieste , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-7850","authenticated-orcid":false,"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[{"name":"General University Hospital and Charles University, Opletalova 38 , 110 00 Star\u00e9 M\u011bsto , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-4901","authenticated-orcid":false,"given":"Andre","family":"Keren","sequence":"additional","affiliation":[{"name":"Cardiology Division, Hadassah Hebrew University Hospital, Sderot Churchill 8 , Jerusalem , Israel"},{"name":"Heart Failure Center, Clalit Health Services, Bnei Brit St 22 , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3131","authenticated-orcid":false,"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Giacomo Puccini, 50 , 34148 Trieste , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Giacomo Puccini, 50 , 34148 Trieste , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2022113023525463000_ehac543-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"2022113023525463000_ehac543-B2","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B3","article-title":"Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy","volume":"6","author":"Porcari","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"2022113023525463000_ehac543-B4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023525463000_ehac543-B5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/ccd.28692","article-title":"Hemodynamics of constrictive pericarditis and restrictive cardiomyopathy","volume":"95","author":"Goldstein","year":"2020","journal-title":"Catheter Cardiovasc Intervent"},{"key":"2022113023525463000_ehac543-B6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2016.01.076","article-title":"Constrictive pericarditis versus restrictive cardiomyopathy?","volume":"67","author":"Garcia","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2016.08.050","article-title":"Differentiation of constriction and restriction: complex cardiovascular hemodynamics","volume":"68","author":"Geske","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: part 1 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00059-012-3663-4","article-title":"Advances in the differentiation of constrictive pericarditis and restrictive cardiomyopathy","volume":"37","author":"Zwas","year":"2012","journal-title":"Herz"},{"key":"2022113023525463000_ehac543-B10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022113023525463000_ehac543-B11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCRESAHA.117.310982","article-title":"Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Muchtar","year":"2017","journal-title":"Circ Res"},{"key":"2022113023525463000_ehac543-B12","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.jtcvs.2015.08.085","article-title":"Ventricular assistant in restrictive cardiomyopathy: making the right connection","volume":"151","author":"Jaquiss","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2022113023525463000_ehac543-B13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.healun.2012.09.018","article-title":"Outcomes of adults with restrictive cardiomyopathy after heart transplantation","volume":"31","author":"DePasquale","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"2022113023525463000_ehac543-B14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","volume":"8","author":"Barrett","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022113023525463000_ehac543-B15","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial amyloidosis: the exemplar interstitial disease","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023525463000_ehac543-B16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B17","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2022113023525463000_ehac543-B19","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"2022113023525463000_ehac543-B20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"2022113023525463000_ehac543-B21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2022113023525463000_ehac543-B22","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022113023525463000_ehac543-B23","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2022113023525463000_ehac543-B24","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2022113023525463000_ehac543-B25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2022113023525463000_ehac543-B26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022113023525463000_ehac543-B27","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2022113023525463000_ehac543-B28","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"2022113023525463000_ehac543-B29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"2022113023525463000_ehac543-B30","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022113023525463000_ehac543-B31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"10","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2022113023525463000_ehac543-B32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2022113023525463000_ehac543-B33","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbrc.2005.10.116","article-title":"Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy","volume":"338","author":"Yumoto","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2022113023525463000_ehac543-B35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0167-5273(98)00013-8","article-title":"Collagen subtypes and matrix metalloproteinase in idiopathic restrictive cardiomyopathy","volume":"64","author":"Hayashi","year":"1998","journal-title":"Int J Cardiol"},{"key":"2022113023525463000_ehac543-B36","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1113\/jphysiol.2012.234252","article-title":"Myosin-driven rescue of contractile reserve and energetics in mouse hearts bearing familial hypertrophic cardiomyopathy-associated mutant troponin T is mutation-specific","volume":"590","author":"He","year":"2012","journal-title":"J Physiol"},{"key":"2022113023525463000_ehac543-B37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCRESAHA.110.224170","article-title":"Thin filament mutations: developing an integrative approach to a complex disorder","volume":"10","author":"Tardiff","year":"2011","journal-title":"Circ Res"},{"key":"2022113023525463000_ehac543-B38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10741-005-5253-5","article-title":"Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes","volume":"10","author":"Tardiff","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2022113023525463000_ehac543-B39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/jmg.2004.030171","article-title":"Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations","volume":"42","author":"Chassaing","year":"2005","journal-title":"J Med Genet"},{"key":"2022113023525463000_ehac543-B40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2022113023525463000_ehac543-B41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0967-2109(96)82320-9","article-title":"Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis","volume":"4","author":"Chello","year":"1996","journal-title":"Cardiovasc Surg"},{"key":"2022113023525463000_ehac543-B42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2018.01.017","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: part 2 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B44","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ejheart.2005.06.004","article-title":"Ventricular remodeling in Loeffler endocarditis: implications for therapeutic decision making","volume":"7","author":"Lofiego","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2022113023525463000_ehac543-B45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics 1995-2017","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"key":"2022113023525463000_ehac543-B46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022113023525463000_ehac543-B47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2022113023525463000_ehac543-B48","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"2022113023525463000_ehac543-B50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J Med Genet"},{"key":"2022113023525463000_ehac543-B51","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metabol Rep"},{"key":"2022113023525463000_ehac543-B52","doi-asserted-by":"crossref","first-page":"e009430","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2022113023525463000_ehac543-B53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Develop"},{"key":"2022113023525463000_ehac543-B54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2022113023525463000_ehac543-B55","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1242\/jcs.184770","article-title":"Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy","volume":"129","author":"Rowland","year":"2016","journal-title":"J Cell Sci"},{"key":"2022113023525463000_ehac543-B56","first-page":"1993","volume-title":"GeneReviews\u00ae [Internet].","author":"Taylor","year":"2020"},{"key":"2022113023525463000_ehac543-B57","volume-title":"StatPearls [Internet]","author":"D\u2019Souza","year":"2022"},{"key":"2022113023525463000_ehac543-B58","first-page":"1204","article-title":"Cardiac arrhythmias in patients with Danon disease","volume":"19","author":"Konrad","year":"2017","journal-title":"Europace"},{"key":"2022113023525463000_ehac543-B59","doi-asserted-by":"crossref","first-page":"A10727","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Results from first-in-human clinical trial of RP-A501 (AAV9:LAMP2B) gene therapy treatment for Danon disease","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation"},{"key":"2022113023525463000_ehac543-B60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm920","article-title":"L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy","volume":"9","author":"Oudit","year":"2003","journal-title":"Nat Med"},{"key":"2022113023525463000_ehac543-B61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00877096","article-title":"Iron overload cardiomyopathies: new insights into an old disease","volume":"8","author":"Liu","year":"1994","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022113023525463000_ehac543-B62","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B63","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"J Card Fail"},{"key":"2022113023525463000_ehac543-B64","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0002-8703(87)90039-1","article-title":"Reversible cardiac dysfunction in hemochromatosis","volume":"113","author":"Rivers","year":"1987","journal-title":"Am Heart J"},{"key":"2022113023525463000_ehac543-B65","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"2022113023525463000_ehac543-B66","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"2022113023525463000_ehac543-B67","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0735-1097(98)00026-6","article-title":"Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits","volume":"31","author":"Arbustini","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022113023525463000_ehac543-B68","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.1543","article-title":"Prognostic impact of short-term changes of E\/E\u2032 ratio and left atrial size in dilated cardiomyopathy","volume":"21","author":"Merlo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022113023525463000_ehac543-B69","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2022113023525463000_ehac543-B70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022113023525463000_ehac543-B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10235-9","article-title":"Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. A position paper of Myocardial and Pericardial Diseases and Cardiac Magnetic Resonance Working Groups of Italian Society of Cardiology","author":"Merlo","journal-title":"Heart Fail Rev"},{"key":"2022113023525463000_ehac543-B72","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s11547-020-01287-8","article-title":"Cardiovascular magnetic resonance (CMR) in restrictive cardiomyopathies","volume":"125","author":"Galea","year":"2020","journal-title":"Radiol Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/45\/4679\/47466584\/ehac543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/45\/4679\/47466584\/ehac543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T21:18:32Z","timestamp":1727990312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/45\/4679\/6767880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":72,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac543","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,21]]}}}